Paul McGarty Archives - CDR – Chain Drug Review

Lupin InspiraChamber gets preferred status at Albertsons

May 31, 2017 by Chain Drug Review Albertsons, Dan Salemi, InspiraChamber, Lupin Pharmaceuticals, Paul McGarty Leading Headlines, Pharmacy, Supplier News

BALTIMORE — Food and drug retailer Albertsons Cos. has agreed to exclusively provide Lupin Pharmaceuticals Inc.’s InspiraChamber device to asthma and other respiratory patients in its stores. Lupin said Wednesday that Albertsons will offer the InspiraChamber, a valved holding chamber for the enhanced delivery of inhaled aerosol therapies, to patients in its more than 1,700

New name for Generic Pharmaceutical Association

February 14, 2017 by Chain Drug Review AAM, Apotex, Association for Accessible Medicines, biosimilars, Chip Davis, generic drugs, Generic Pharmaceutical Association, GPhA, GPhA Annual Meeting, Heather Bresch, Jeff Watson, Lupin Pharmaceuticals, mylan, Paul McGarty, Peter Goldschmidt, Sandoz Featured Articles, Leading Headlines, Pharmacy, Supplier News

WASHINGTON — The Generic Pharmaceutical Association (GPhA), which represents manufacturers of generic drugs and biosimilars, has changed its name to the Association for Accessible Medicines (AAM). The association said Tuesday that the new name better reflects its mission: to make medications more accessible to the people who need them. As GPhA, the trade group had steadfastly